Oxurion NV — Major Shareholding Notification 2025

Mar 27, 2025

Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC

Leuven, BELGIUM – March 27, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation¹ it has received transparency notifications as follows:

Oxurion received a transparency notification on March 27, 2025, from Atlas Special Opportunities II, LLC indicating that as of March 20, 2025, it held 52,489 shares of the then outstanding 3,638,344 shares, and therefore crossed under the threshold (3%) by virtue of the selling of voting securities.

Oxurion received a transparency notification on March 27, 2025, from Atlas Special Opportunities II, LLC indicating that as of March 24, 2025, it held 1,007,463 shares of the then outstanding 4,634,663 shares, and therefore crossed above the threshold (20%) by virtue of the purchase of voting securities.

About Oxurion

Oxurion (Euronext Brussels: OXUR) is engaged in developing next-generation standard of care ophthalmic therapies for the treatment of retinal disease. Oxurion is based in Leuven, Belgium. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forwardlooking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

For further information please contact:

Oxurion NV Pascal Ghoson Chief Executive Officer Pascal.ghoson@oxurion.com

________

1. Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.

ANNEX 1

FSMA	FINANCIAL SERVICES AND MARKETS AUTHORITY	Transparency notification Form TR-1 BE PART I
1) Status of the notification
	Final
2) Issuer
ldentification number 0881-620-924	Name OXURION
3) Reason for the notification
	Acquisition or disposal of voting securities or voting rights Downward crossing of the lowest threshold
4) Notification by
	A person that notifies alone
5) Persons subject to the notification requirement
	Name	Address (for legal entities)
	Atlas Special Opportunities II LLC	2500 Westchester Avenue, Suite 401, Purchase, NY 10577
	6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)
	Name	Address (for legal entities)
	Please continue entering the information in part II concerning the persons referred to in Sections 5 and 6	Part II
7) Date on which the threshold is crossed
		20/03/2025 (DD/MMYYYY)
8) Threshold that is crossed (in %)
		3
	If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10
9) Denominator
	3,638,344
	Please enter the denominator before filling in the data
10) Notified details
A) Voting rights	Previous notification	After the transaction
	# of voting rights	# of voting rights	% of voting rights

B) Equivalent financial instruments	After the transaction
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
							+
	TOTAL
	The totals will be undated once you have clicked on

TOTAL (A & B)		# of voting rights % of voting rights
	CALCULATE	52,489	1.44%

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Atlas Special Opportunities II LLC is not a controlled entity.
12) In case of proxy voting for only one GM
will cease to hold / voting rights as of Holder will hold again	(DD/MM/YYYY)
13) Additional information
On 14 March 2025 (with settener) date on 18 March 2020) Allas Special Operium NY, as a result of which its stares of of Mich its starending decreased of 13,201 shares (=3.69% denominator = 3,638,344). On 18 March 2025 (with settenent date on 20 March 2025), Allas Special Operity in LC sold of which its shareholding decreased on 52,498 shares (= 1.48%, denominator = 3,638,344).
Done at New York

On 27/03/2025 (DD/MMYYYYY) Name & capacity Patrick Vance, Proxyholder Signature

Patrick: Vance

For security reasons, the unsigned form in xlsx format should be
transmitted to tre.fin@fsma.be. You can do this manually
OR if you have MS Outlook at your disposal via th

In addition, a signed copy in PDE format should also be
transmitted.

ANNEX 2

FSMA FINANCIAL SERVICES AND MARKETS AUTHORITY		Transparency notification Form TR-1 BE PART I
1) Status of the notification
Final
2) Issuer
Name OXURION Identification number 0881-620-924
3) Reason for the notification
	Acquisition or disposal of voting securities or voting rights
4) Notification by
	A person that notifies alone
5) Persons subject to the notification requirement
	Name	Address (for legal entities)
	Atlas Special Opportunities II LLC	2500 Westchester Avenue, Suite 401, Purchase, NY 10577
	6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)
	Name	Address (for legal entities)
1	Please continue entering the information in part II concerning the persons referred to in Sections 5 and 6	Part II
7) Date on which the threshold is crossed
		24/03/2025 (DD/MMYYYY)
8) Threshold that is crossed (in %)
	20
		If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10
9) Denominator
	4,634,663
	Please enter the denominator before filling in the data

10) Notified details

A) Voting rights	Previous notification	After the transaction
	# of voting rights	# of voting rights		% of voting rights
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Atlas Special Opportunities II LLC	52.489	1,007,463		21 74%
TOTAL		1,007,463	0	21.74%	0.00%

Start with "groups" of holders. Add subtotals with Σ, and then finish with the persons who are "alone".
For groups, start with the ultimate controlling natural person or le

B) Equivalent financial instruments	After the transaction
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
							+
	TOTAL			0	0.00%

● The totals will be updated once you have clicked on

TOTAL (A & B)			# of voting rights % of voting rights
	CALCULATE	1,007,463	21.74%

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

12) In case of proxy voting for only one GM

B

Holder		will cease to hold / will hold again		(DD/MM/YYYY) voting rights as of
13) Additional information
denominator = 3,638,344). 21.74%, denominator = 4,634,663).				In 19 March 2026 (with settlement date on 21 March 2025), Atlas Special Open 1,345 stares in Onion NV, as a result of which its shares of of 1,144 shares (=0.3%, On 201 March 2026 (with settlement date on 24 March 1995, 19 stares in Orgines in Orarion NY, as a result of which its starely bir noreased on 1,07, 463 shares (=
	Done at New York
On		27/03/2025 (DD/MMYYYY)
	Name & capacity Patrick Vance, Proxyholder		Signature	Patrick Vance ARCZ PRODUCTION AND
				For security reasons, the unsigned form in xlsx format should be transmitted to trp.fin@fsma.be. You can do this manually OR if you have MS Outlook at your disposal via the "Save & Send" button. In addition, a signed copy in PDE format should also be transmitted.

+